Email
Print
Cat Allergy in Humans Market - Forecast(2024 - 2030)
Cat Allergy in Humans Market Overview:
Cat Allergy in Humans Market size is valued at $36.91 billion in 2022 and is expected to reach a value of $62.87 billion by 2030 at a CAGR of 6.8% during the forecast period 2023-2030. The Cat Allergy in Humans Market is a segment of the broader allergy therapeutics market. It includes products and services aimed at diagnosing, managing, and treating allergies that result from exposure to cats or their allergens. Cat allergies are caused by the immune system's hypersensitivity to proteins found in cat saliva, urine, and dander (skin flakes).
Cat allergies are one of the most common types of pet allergies, affecting a significant number of people worldwide. Symptoms of cat allergies can range from mild to severe and may include sneezing, nasal congestion, itchy and watery eyes, skin rashes, and even asthma in some cases. The presence of cats in households can substantially impact the quality of life for individuals who are allergic, leading to reduced well-being and increased healthcare costs.
The Cat Allergy in Humans Market involves various pharmaceutical companies, diagnostic laboratories, and healthcare providers. Pharmaceutical companies develop and manufacture allergy medications, while diagnostic laboratories perform allergy testing to diagnose cat allergies accurately. Healthcare providers, such as allergists and immunologists, play a crucial role in managing cat allergies and determining appropriate treatment plans.
Market Snapshot:
Cat Allergy in Humans Market - Report Coverage:
The “Cat Allergy in Humans Market Report - Forecast (2023-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Cat Allergy in Humans Market.
Cat Allergy in Humans Market - Top Trends:
Rising Prevalence of Cat Allergies: The prevalence of cat allergies has been increasing globally due to the growing popularity of cats as pets. This trend has driven the demand for effective allergy management and treatment solutions.
Increased Awareness and Diagnosis: Improved awareness about cat allergies and advancements in diagnostic techniques have led to earlier and accurate identification of cat allergies in affected individuals. This has resulted in a higher number of patients seeking appropriate medical attention and treatment.
Growth in Allergy Immunotherapy: Allergy immunotherapy, including allergy shots (subcutaneous immunotherapy) and sublingual immunotherapy, has gained popularity as an effective long-term treatment for cat allergies. It offers the potential for symptom reduction and increased tolerance to cat allergens over time.
Advancements in Medications: Pharmaceutical companies have been investing in research and development to create more effective and targeted medications for cat allergy relief. New antihistamines, nasal corticosteroids, and other allergy medications have been introduced to the market.
Personalized Medicine: The concept of personalized medicine, tailoring treatment plans based on an individual's specific allergies and responses, has been gaining traction. This approach aims to provide more targeted and effective treatments for cat allergies.
Growing Telemedicine Services: Telemedicine and telehealth services have become more prevalent, making it easier for individuals with cat allergies to consult with healthcare professionals remotely. This trend has increased access to specialized care, especially in areas with limited access to allergists.
Cat Allergy in Humans Market - Company Product Analysis:
Novartis Pharmaceuticals Corporation: Xolair is an injectable medication that is used to treat moderate to severe persistent allergic asthma and chronic idiopathic urticaria (hives) in adults and adolescents. In some cases, it might be prescribed for cat allergy-related asthma.
GlaxoSmithKline (GSK): Flonase is a nasal corticosteroid spray that provides relief from allergy symptoms such as nasal congestion, sneezing, runny nose, and itchy nose due to various allergens, including cat allergens.
Sanofi: Allegra is an antihistamine medication used to relieve allergy symptoms caused by seasonal allergies and chronic idiopathic urticaria (hives). It may help alleviate cat allergy symptoms.
Johnson & Johnson (J&J): Zyrtec is an antihistamine used to treat allergy symptoms caused by various allergens, including cat allergens. It provides relief from symptoms such as sneezing, runny nose, and itchy or watery eyes.
Stallergenes Greer: Oralair is an allergy immunotherapy tablet used to treat allergic rhinitis (hay fever) caused by specific grass pollen allergies, which might include grasses that cross-react with cat allergens.
ALK: Grazax is an allergy immunotherapy tablet used to treat allergic rhinitis caused by specific grass pollen allergies, which may include grasses that cross-react with cat allergens.
Key Market Players:
Product/Service launches, approvals, patents and events, acquisitions, partnerships and collaborations are key strategies adopted by players in the Cat Allergy in Humans Market. The top 10 companies in this industry are listed below:
- Novartis AG
- GlaxoSmithKline (GSK)
- Sanofi
- Johnson & Johnson (J&J)
- Stallergenes Greer
- ALK
- Allergy Therapeutics
- HAL Allergy Group
- DBV Technologies
- Aimmune Therapeutics
Scope of Report:
For more Lifesciences and Healthcare related reports, please click here
1. Cat Allergy in Humans Market - Overview
1.1 Definitions and Scope
2. Cat Allergy in Humans Market - Executive Summary
3. Cat Allergy in Humans Market - Comparative Analysis
3.1 Company Benchmarking - Key Companies
3.2 Global Financial Analysis - Key Companies
3.3 Market Share Analysis - Key Companies
3.4 Patent Analysis
3.5 Pricing Analysis
4. Cat Allergy in Humans Market - Start-up Companies Scenario (Premium)
4.1 Key Start-up Company Analysis by
4.2 Investment
4.3 Revenue
4.4 Venture Capital and Funding Scenario
5. Cat Allergy in Humans Market – Market Entry Scenario Premium (Premium)
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing Business Index
5.3 Case Studies of Successful Ventures
6. Cat Allergy in Humans Market - Forces
6.1 Market Drivers
6.2 Market Constraints
6.3 Market Challenges
6.4 Porter's Five Force Model
6.5 Bargaining Power of Suppliers
6.6 Bargaining Powers of Customers
6.7 Threat of New Entrants
6.8 Rivalry Among Existing Players
6.9 Threat of Substitutes
7. Cat Allergy in Humans Market – Strategic Analysis
7.1 Value Chain Analysis
7.2 Opportunities Analysis
7.3 Market Life Cycle
8. Cat Allergy in Humans Market – By Treatment Type (Market Size – $Million/$Billion)
8.1 Antihistamines
8.1.1 Market Size and Forecast, By Region
8.1.2 Market Share Analysis, By Country
8.2 Corticosteroid Nasal Sprays
8.2.1 Market Size and Forecast, By Region
8.2.2 Market Share Analysis, By Country
8.3 Decongestants
8.3.1 Market Size and Forecast, By Region
8.3.2 Market Share Analysis, By Country
8.4 Leukotriene Inhibitors
8.4.1 Market Size and Forecast, By Region
8.4.2 Market Share Analysis, By Country
8.5 Others
8.5.1 Market Size and Forecast, By Region
8.5.2 Market Share Analysis, By Country
9. Cat Allergy in Humans Market – By Application (Market Size – $Million/$Billion)
9.1 Allergy Treatment
9.1.1 Market Size and Forecast, By Region
9.1.2 Market Share Analysis, By Country
9.2 Allergy Prevention
9.2.1 Market Size and Forecast, By Region
9.2.2 Market Share Analysis, By Country
10. Cat Allergy in Humans Market – By Distribution Channel (Market Size – $Million/$Billion)
10.1 Hospital Pharmacies
10.1.1 Market Size and Forecast, By Region
10.1.2 Market Share Analysis, By Country
10.2 Retail Pharmacies
10.1.1 Market Size and Forecast, By Region
10.1.2 Market Share Analysis, By Country
10.3 Online Pharmacies
10.3.1 Market Size and Forecast, By Region
10.3.2 Market Share Analysis, By Country
11. Cat Allergy in Humans Market – By End User (Market Size – $Million/$Billion)
11.1 Patients
11.1.1 Market Size and Forecast, By Region
11.1.2 Market Share Analysis, By Country
11.2 Healthcare Providers
11.2.1 Market Size and Forecast, By Region
11.2.2 Market Share Analysis, By Country
11.3 Immunotherapy Clinics
11.3.1 Market Size and Forecast, By Region
11.3.2 Market Share Analysis, By Country
12. Cat Allergy in Humans Market – by Geography (Market Size – $Million/$Billion)
12.1 North America
12.1.1 The U.S.
12.1.2 Canada
12.1.3 Mexico
12.2 Europe
12.2.1 UK
12.2.2 Germany
12.2.3 France
12.2.4 Italy
12.2.5 Spain
12.2.6 Russia
12.2.7 Rest of Europe
12.3 Asia-Pacific
12.3.1 China
12.3.2 India
12.3.3 Japan
12.3.4 South Korea
12.3.5 Australia & New Zealand
12.3.6 Rest of Asia-Pacific
12.4 South America
12.4.1 Brazil
12.4.2 Argentina
12.4.3 Chile
12.4.4 Colombia
12.4.5 Rest of South America
12.5 Rest of the World
12.5.1 Middle East
12.5.2 Africa
13. Cat Allergy in Humans Market – Entropy
14. Cat Allergy in Humans Market – Industry/Segment Competition Landscape Premium
14.1 Market Share Analysis
14.1.1 Market Share by Product Type – Key Companies
14.1.2 Market Share by Region – Key Companies
14.1.3 Market Share by Country – Key Companies
14.2 Competition Matrix
14.3 Best Practices for Companies
15. Cat Allergy in Humans Market – Key Company List by Country Premium Premium
16. Cat Allergy in Humans Market - Company Analysis
16.1 Novartis AG
16.2 GlaxoSmithKline (GSK)
16.3 Sanofi
16.4 Johnson & Johnson (J&J)
16.5 Stallergenes Greer
16.6 ALK
16.7 Allergy Therapeutics
16.8 HAL Allergy Group
16.9 DBV Technologies
16.10 Aimmune Therapeutics
16.11 Circassia Pharmaceuticals
16.12 Allergan plc
16.13 Teva Pharmaceutical Industries Ltd.
16.14 Merck & Co., Inc.
16.15 Mylan N.V. (now Viatris Inc.)
16.16 AstraZeneca plc
16.17 Pfizer Inc.
16.18 Boehringer Ingelheim International GmbH
16.19 Cipla Inc.
16.20 Dr. Reddy's Laboratories Ltd.
• "Financials to the Private Companies would be provided on best-effort basis."
Connect with our experts to get customized reports that best suit your requirements. Our
reports include global-level data, niche markets and competitive landscape.
The Cat Allergy in Humans is forecast to grow at 6.8% during the forecast period 2023-2030.
Global Cat Allergy in Humans Market size is estimated to reach $62.87 Billion by 2030.
The leading players in the Cat Allergy in Humans Market are Thermo Fisher Scientific, Agilent Technologies, PerkinElmer, Bruker Corporation, Shimadzu Corporation.